08:38 AM EDT, 05/23/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Thursday that additional data from the EMERGENT-5 trial supports KarXT's potential as a unique schizophrenia treatment.

The long-term trials, consistent with short-term studies, showed no significant changes in movement disorder scale scores and a low incidence of extrapyramidal symptoms.

In qualitative interviews, participants noted improvements in positive, negative, and cognitive symptoms with KarXT in the EMERGENT-5 trial, the company said.

The company will present the data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting.

Shares of Bristol-Myers Squibb ( BMY ) were up 0.4% in Thursday premarket activity.

Price: 42.50, Change: +0.16, Percent Change: +0.38